Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mentice ABFRA:MN2 +3.15%75 Interest Coverage is 0.27 as of Jun. 2026, which is 100% below its 10-year median of 549.00. GuruFocus rates FRA:MN2 with a GF Score™ of 75/100 and a GF Value™ of €1.94 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 463 Medical Devices & Instruments companies, Mentice AB ranks worse than 215982.51% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Mentice AB's
Operating Income
for the
three
months ended in Jun. 2026 was €0.03 Mil. Mentice AB's Interest Expense for the
three
months ended in Jun. 2026 was €-0.09 Mil.
Mentice AB's interest coverage for the quarter that ended in Jun. 2026 was 0.27.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Mentice AB's Interest Coverage or its related term are showing as below:
FRA:MN2's Interest Coverage is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 16.85 * Ranked among companies with meaningful Interest Coverage only.
Mentice AB (FRA:MN2) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Mentice AB Interest Coverage Related Terms
Mentice AB Interest Coverage Historical Data
* Premium members only.
The historical data trend for Mentice AB's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:MN2 vs ABT, SYK, MDT: Interest Coverage Comparison
For the Medical Devices subindustry, Mentice AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mentice AB Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mentice AB's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Mentice AB's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mentice AB (FRA:MN2) has a Interest Coverage of 0.27 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Mentice AB and its competitors. This is 100% below median its historical median of 549.00. According to the industry distribution chart, Mentice AB ranks #999999 out of 463 companies in the Medical Devices & Instruments industry.
Is Mentice AB's Interest Coverage too high?
Mentice AB's current Interest Coverage of 0.27 is 100% below median its 10-year median of 549.00. The Medical Devices & Instruments industry median Interest Coverage is 16.85. Mentice AB's value of 0.27 is 98.4% below this industry median. Based on the distribution chart, Mentice AB ranks #999999 out of 463 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Mentice AB has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mentice AB's Interest Coverage compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mentice AB ranks #999999 out of 463 companies for Interest Coverage. This places Mentice AB in the lower half of its industry. The industry median Interest Coverage is 16.85. Mentice AB's value of 0.27 is 98.4% below this benchmark. While the company's 10-year median is 549.00 vs. the industry median of 16.85, Mentice AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 16.85, based on 463 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mentice AB's current Interest Coverage of 0.27 is 98.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Mentice AB and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 16.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mentice AB's current Interest Coverage is 0.27, which is 100% below median its own 10-year median of 549.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mentice AB stock overvalued right now?
Based on GuruFocus' analysis, Mentice AB (FRA:MN2) is currently considered Significantly Undervalued. The stock's GF Value™ is €1.94, compared to a current price of €1.31 — trading 32.5% below its estimated fair value. The current Interest Coverage is 0.27, which is 100% below median its 10-year median of 549.00 and 98.4% below the Medical Devices & Instruments industry median of 16.85. Mentice AB's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Mentice AB (FRA:MN2), the current Interest Coverage is 0.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mentice AB (FRA:MN2) Overvalued in 2026?
Based on GuruFocus' analysis, Mentice AB stock appears to be undervalued.
The current stock price of €1.31 is trading 32.5% below its estimated GF Value™ of €1.94.
GuruFocus considers Mentice AB to be Significantly Undervalued.
Key valuation signals for FRA:MN2:
Interest Coverage: 0.27 (100% below median its 10-year median of 549.00)
GF Value™: €1.94 vs. price of €1.31 (32.5% below fair value)
Industry Position: 98.4% below the Medical Devices & Instruments median (#999999 of 463)
No single metric tells the full story. See the FRA:MN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mentice AB is a provider of software and hardware simulation solutions for image guided interventional therapies, offering proficiency based simulation solutions that help healthcare professionals acquire, retain, and enhance procedural skills, improving productivity and outcomes. Its solutions are scientifically validated and developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are covered. Mentice operates in two segments: Medical Device Industry (MDI), providing end-to-end solutions supporting development and launch of interventional therapies, and Healthcare Systems (HCS). Product areas include Mentice VIST, Physical Sim, Mentice Live, and Ankyras. It operates in EMEA, APAC, and the Americas.
75GF Score
Get the complete analysis for FRA:MN2
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MN2 has been successfully added to your 
